|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
16 December 2017 |
|
Main ID: |
NCT02543073 |
|
Date of registration:
|
04/09/2015 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
MSC for Treatment of Interstitial Lung Disease After Allo-HSCT
|
|
Scientific title:
|
Mesenchymal Stem Cell for Treatment of Interstitial Lung Disease After Allogenetic Hematopoietic Stem Cell Transplantation |
|
Date of first enrolment:
|
September 2014 |
|
Target sample size:
|
60 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://clinicaltrials.gov/show/NCT02543073 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
|
Phase:
|
Phase 1/Phase 2
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Ren Lin, MD |
|
Address:
|
|
|
Telephone:
|
+86-020-61641613 |
|
Email:
|
lansinglinren@hotmail.com |
|
Affiliation:
|
|
|
|
Name:
|
Ren Lin |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
lansinglinren@hotmail.com |
|
Affiliation:
|
|
|
|
Name:
|
Qifa Liu, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Nanfang Hospital of Southern Medical University |
|
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Receiving allo-HSCT
- Diagnosed with ILD after allo-HSCT
Exclusion Criteria:
- Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood
pressure)
- Patients with any conditions not suitable for the trial (investigators' decision)
Age minimum:
18 Years
Age maximum:
65 Years
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Bronchiolitis Obliterans
|
|
Hematopoietic Stem Cell Transplantation
|
|
Lung Diseases, Interstitial
|
|
Intervention(s)
|
|
Biological: MSCs
|
|
Drug: Glucocorticoid
|
|
Drug: AZM
|
|
Primary Outcome(s)
|
|
Response rate of ILD
[Time Frame: 4 weeks]
|
|
Secondary Outcome(s)
|
|
Overall Survival
[Time Frame: 3 year]
|
|
Secondary ID(s)
|
|
MSC-ILD-2015
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|